OR| Oregon DFR Issues Bulletin DFR 2026-2 stating that OR has withdrawn Bulletin DFR2024-3 which provided guidance to prescription drug manufacturers subject to the Oregon Drug Price Transparency Program regarding a 2024 U.S. District Court ruling that resulted in the indefinite suspension of the program’s annual price increase reporting. Insurers must immediately resume regularly submissions of price increase reports.